Press Releases
DiscGenics CEO and Chairman, Flagg Flanagan will present at Canaccord Genuity 2024 Musculoskeletal Conference taking place in San Francisco on Monday, February 12, 2024.
DiscGenics CEO and Chairman, Flagg Flanagan will present at Biotech Showcase 2024 taking place in San Francisco, CA on Wednesday, January 10, 2024.
DiscGenics has announced a basic science Cooperative Research and Development Agreement (CRADA) with the U.S. Department of Veterans Affairs (VA) to assess the feasibility of using DiscGenics’ proprietary Discogenic Cells with the VA’s whole, tissue-engineered endplate-modified disc-like angle ply structure (eDAPS).
DiscGenics CEO and Chairman, Flagg Flanagan will present at Canaccord Genuity’s 18th Annual Musculoskeletal Conference taking place in Las Vegas, NV on Tuesday, March 7, 2023.
U.S. FDA grants Regenerative Medicine Advanced Therapy (RMAT) designation to IDCT, the first and only product intended for spine care to receive the special regulatory designation.
Discogenic progenitor cell therapy safely increased disc volume and provided rapid, durable improvements in low back pain, function, quality of life, and pain medication usage out to two years post-injection in patients with lumbar DDD.
DiscGenics Chief Executive Officer and Chairman Flagg Flanagan will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 at 3:30 p.m. PST.
Matthew F. Gornet, MD will present two-year follow-up data from DiscGenics’s first-in-human clinical study of its allogeneic discogenic progenitor cell therapy (IDCT) for lumbar disc degeneration at the North American Spine Society Annual Meeting on October 12, 2022.
Flagg Flanagan will provide a virtual update on DiscGenics’s first-in-human clinical study of its allogeneic discogenic progenitor cell therapy for lumbar disc degeneration at the annual Cell & Gene Meeting on the Mesa.
IDCT was well tolerated and produced clinically meaningful, statistically significant improvements in low back pain, function, and quality of life by 12 weeks following intradiscal injection; improvements were sustained at the one-year interim readout with additional data to follow at 18 and 24 months.
DiscGenics Chief Executive Officer and Chairman Flagg Flanagan will present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022 at 9:00 a.m. EST.
Goldman Sachs (NYSE:GS) has recognized DiscGenics Chairman and CEO Flagg Flanagan as one of the 100 Most Intriguing Entrepreneurs of 2021.
DiscGenics has enrolled a total of 38 subjects in its Japanese clinical study of IDCT. Meanwhile in the U.S., all currently enrolled trial subjects have completed their one-year study visits.
DiscGenics has raised $50 million in a Series C funding round bringing investment in the Company to just over $71 million to-date. Concurrent with this investment, DiscGenics has also added two new members to its Board of Directors.
DiscGenics has completed patient enrollment in its Phase 1/2 first-in-human U.S. clinical study of IDCT, an allogeneic, injectable Discogenic Cell therapy for degenerative disc disease.
An independent data safety monitoring committee (DSMC) has given DiscGenics the go-ahead to enroll the final 24 patients in its first-in-human U.S. clinical study of IDCT.
DiscGenics Chairman and CEO Flagg Flanagan will present at the 2019 Musculoskeletal New Ventures Conference on Tuesday, October 29, 2019 in Memphis, TN.
A study has been published in The Spine Journal that summarizes the results of preclinical testing for Discogenic Cells, the active ingredient in IDCT, DiscGenics’ investigational cell therapy for disc degeneration.
The first 30 subjects have been safely treated DiscGenics’ first-in-human U.S. clinical study of IDCT, an allogeneic, injectable disc cell therapy for mild to moderate degenerative disc disease (DDD).
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for DiscGenics’ investigational cell therapy, IDCT, currently being evaluated in regulator-allowed clinical trials in the U.S. and Japan for the reduction in pain and disability associated with degenerative disc disease (DDD), a major cause of chronic low back pain.
The first patients have been treated in DiscGenics’ Japanese safety study, a clinical trial of IDCT for mild to moderate degenerative disc disease in Japan.
The first Utahns have been treated in DiscGenics' nationwide clinical study of IDCT, a locally developed injectable disc cell therapy for degenerative disc disease (DDD).
Chief Medical Officer, Kevin T. Foley, MD, FACS, FAANS was awarded the 2019 AANS Cushing Award for Technical Excellence and Innovation in Neurosurgery. The award honors an AANS member for technical prowess and skill and/or innovation in the development of new procedures that have become part of the arsenal a neurosurgeon uses to treat disease or trauma.
DiscGenics is expanding operations in Salt Lake City with an approximately 25,000 sq. ft. space where it intends to build a research and development facility along with manufacturing operations.
IDCT has passed the initial planned safety review of a Phase I/II trial evaluating the allogeneic, injectable disc cell therapy in patients with mild to moderate degenerative disc disease.
The Japanese Pharmaceuticals and Medical Devices Agency (PMDA) has approved DiscGenics' Clinical Trial Notification (CTN) application for IDCT, an allogeneic injectable disc cell therapy for the treatment of degenerative disc disease (DDD) in Japan.
Flagg Flanagan, Chairman and CEO of DiscGenics, will present at the annual Partnering Forum, part of the Cell & Gene Meeting on the Mesa, on Wednesday, October 3, 2018 at 4:15pm PDT in La Jolla, CA.
DiscGenics has engaged with CCRM and GE Healthcare, leaders in developing and commercializing cell and gene therapy technologies, to support the Company’s efforts to scale and optimize manufacturing of its homologous, allogeneic (off-the- shelf), injectable cell therapy.
Events & Presentations
41st Annual J.P. Morgan Healthcare Conference
January 9 - 12, 2023
San Francisco, CA
2023 Sierra Spine Society Winter Symposium
March 3 - 5, 2023
Mammoth Lakes, CA
Canaccord Genuity 2023 Musculoskeletal Conference
March 7, 2023
Las Vegas, NV
Spine Summit 2023
March 16 - 19, 2023
Miami Beach
Association of Chiropractic Colleges/Research Agenda Conference
March 23 - 25, 2023
New Orleans, LA
2023 HEALinc Future Health Summit
April 17 - 19, 2023
Bahamas
2023 AANS Annual Scientific Meeting
April 21 - 24, 2023
Los Angeles, CA
Advanced Therapies in Orthopaedics Foundation (ATiO) Conference 2023
May 15 - 20, 2023
Berlin, Germany
International Society for the Advancement of Spine Surgery (ISASS) 23rd Annual Conference
June 1 - 3, 2023
San Francisco, CA
The 17th Annual State of Spine Surgery Think Tank
June 28 - July 1, 2023
San Jose del Cabo, Mexico
The American Society of Pain & Neuroscience (ASPN) Annual Conference
July 13 - 16, 2023
Miami, FL
North American Spine Society (NASS) 38th Annual Meeting
October 18 - 21, 2023
Los Angeles, CA
